Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    Special Populations
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    March 10, 2023
    How I Practice Mindfulness as an Oncology Nurse
    Nurse well-being
    How I Practice Mindfulness as an Oncology Nurse
    March 03, 2023
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • News & Views

    Clinical practice

    BTK Inhibitor Effective for Relapsed Hairy Cell Leukemia
    Research

    BTK Inhibitor Effective for Relapsed Hairy Cell Leukemia

    Ibrutinib produces durable disease control for patients with high-risk hairy cell leukemia, a rare cancer, who have relapsed and for whom standard purine analogues are not a feasible therapeutic option, according to study results published in Blood.

    September 08, 2021
    Hope in Rare Cancers: Care Is Complex, but Oncology Nurses Are Making a Difference
    Cancer research

    Hope in Rare Cancers: Care Is Complex, but Oncology Nurses Are Making a Difference

    As individual diseases, cancer diagnoses like pheochromocytoma (cancer of the adrenal gland), neuroendocrine cancers, and malignant mixed Mullerian tumors (also called carcinosarcomas) are rare, but collectively they’re more common than breast, colon, lung, or prostate cancer.

    September 07, 2021
    FDA Approves Zanubrutinib for Waldenström Macroglobulinemia
    U.S. Food and Drug Administration (FDA)

    FDA Approves Zanubrutinib for Waldenström Macroglobulinemia

    On August 31, 2021, the U.S. Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa®) for adult patients with Waldenström macroglobulinemia (WM).

    September 02, 2021
    Study Shows Anti-Vaping Advertising Campaigns Are Effective in Educating Youth About Tobacco Dangers
    Cancer health policy

    Study Shows Anti-Vaping Advertising Campaigns Are Effective in Educating Youth About Tobacco Dangers

    Young people who see anti-vaping advertisements and prevention campaigns are more likely to have accurate e-cigarette knowledge, which can lead to a decrease in tobacco use and consequently, lung cancer diagnoses, according to a July 2021 study from the Truth Initiative, an organization devoted to educating youth about smoking and tobacco industries.

    September 02, 2021
    Study Ranks U.S. Healthcare Industry Dead Last Among Other High-Income Countries
    Healthcare safety standards

    Study Ranks U.S. Healthcare Industry Dead Last Among Other High-Income Countries

    The United States is worst among 11 high-income countries in delivery of and access to health care, according to an August 2021 study conducted by the Commonwealth Fund, despite spending the most, by far, of its gross domestic product (GDP) on health care than other countries surveyed. The survey used indicators across domains on access to care, care process, administrative efficiency, equity, and healthcare outcomes to compare healthcare system performance. Overall, the top-performing countries were Norway, the Netherlands, and Australia.

    September 01, 2021
    It’s Okay to Put Yourself First Sometimes
    Nurse well-being

    It’s Okay to Put Yourself First Sometimes

    Are you at—or well over—the brink of burnout? Do you feel like you give, give, give and cannot find the time to refill? Those are common feelings for nurses, whose profession is a service to humanity. Although our work is rewarding, it’s also physically, emotionally, and mentally draining. Never feel guilty or judge yourself for stepping away and taking time for yourself—it’s essential to maintain the high level of care you provide every day.

    August 26, 2021
    FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma

    On August 25, 2021, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo®) for adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. FDA also approved the Oncomine Dx Target Test as a companion diagnostic device to aid in selecting patients with cholangiocarcinoma for treatment with ivosidenib.

    August 26, 2021
    Testicular Cancer Treatment and Survival Rates Are Improving
    Cancer research

    Testicular Cancer Treatment and Survival Rates Are Improving

    Progression-free and overall survival rates for patients with metastatic testicular cancer have significantly grown since 1990, researchers reported in the Journal of Clinical Oncology.

    August 25, 2021
    Oncology Drug Reference Sheet: Tivozanib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Tivozanib

    On March 10, 2021, the U.S. Food and Drug Administration approved tivozanib (Fotivda®), an oral kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

    August 24, 2021
    The Case of the GVHD Double-Take
    Treatment side effects

    The Case of the GVHD Double-Take

    Jeff is a 60-year-old patient with myeloproliferative disease. After his care team secured a 9/10 match, he received an allogeneic hematopoietic stem cell transplantation with a conditioning regimen of fludarabine and melphalan. Neutrophil engraftment occurred at day 20, and he was discharged to home shortly after engraftment. One month later, he presented to the clinic with abdominal pain and a new diffuse erythematous rash, which his care team initially treated with corticosteroids. However, his abdominal pain persisted, and Jeff was admitted to the hospital a few days later for further workup for suspected acute graft-versus-host disease (GVHD). A computed tomography scan of his abdomen demonstrated worsening enterocolitis because of Yersinia enterocolitica. What would you do?

    August 24, 2021
    FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma

    On August 19, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk for recurrence after undergoing radical resection.

    August 23, 2021
    FDA Expands Recall to Include Four Additional Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content
    U.S. Food and Drug Administration (FDA)

    FDA Expands Recall to Include Four Additional Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content

    On August 16, 2021, the U.S. Food and Drug Administration (FDA) reported Pfizer’s voluntary recall of an additional four lots of varenicline 0.5mg/1 mg tablets to the patient level because of the presence of N-nitroso-varenicline, a nitrosamine, above the Pfizer-established acceptable daily intake level. To date, Pfizer has not received any reports of adverse events that have been related to the recall. FDA reported Pfizer’s recall of 12 lots of varenicline tablets because of N-nitroso varenicline content on July 19, 2021.

    August 19, 2021
    FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumors
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumors

    On August 17, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dostarlimab-gxly (Jemperli®) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

    August 18, 2021
    Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS
    Genetics & genomics

    Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS

    When compared to conventional testing on the same samples from patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), whole-genome sequencing–based testing detected the same abnormalities—and new genetic information in about a quarter of patients, potentially changing treatment selection for more than half of those patients, researchers said in the New England Journal of Medicine.

    August 18, 2021
    FDA Approves Lenvatinib and Pembrolizumab for Advanced Renal Cell Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lenvatinib and Pembrolizumab for Advanced Renal Cell Carcinoma

    On August 10, 2021, the U.S. Food and Drug Administration (FDA) approved the combination of lenvatinib (Lenvima®) and pembrolizumab (Keytruda®) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

    August 13, 2021
    FDA Approves Belzutifan for Cancers Associated With Von Hippel-Lindau Disease
    U.S. Food and Drug Administration (FDA)

    FDA Approves Belzutifan for Cancers Associated With Von Hippel-Lindau Disease

    On August 13, 2021, the U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg®), a hypoxia-inducible factor inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), that do not require immediate surgery.

    August 13, 2021
    Baxter Healthcare Recalls Dose IQ Software Version 9.0.x Because of Software Defect
    U.S. Food and Drug Administration (FDA)

    Baxter Healthcare Recalls Dose IQ Software Version 9.0.x Because of Software Defect

    On August 12, 2021, the U.S Food and Drug Administration (FDA) reported Baxter Healthcare’s recall of the Dose IQ Safety Software used with the Spectrum IQ Infusion System because a software defect may lead to mismatched drug information in drug libraries that were created using version 9.0.x of the computer-based software. FDA identified it as a class I recall, the most serious type of recall, where use of the devices may cause serious injuries or death.

    August 13, 2021
    FDA Announces Recall for SterRX, LLC, Sodium Bicarbonate in 5% Dextrose Injection Because of Microbial Contamination
    U.S. Food and Drug Administration (FDA)

    FDA Announces Recall for SterRX, LLC, Sodium Bicarbonate in 5% Dextrose Injection Because of Microbial Contamination

    On August 10, 2021, the U.S. Food and Drug Administration (FDA) reported SterRx, LLC’s, voluntary recall of three lots of sodium bicarbonate in 5% dextrose injection 150 mEq per 1,000 ml due to waterborne microbial contamination.

    August 12, 2021
    APRN Leaders Mentor Students to Tackle Clinical Practice Issues
    Advanced Practice Nursing (APRN)

    APRN Leaders Mentor Students to Tackle Clinical Practice Issues

    Nursing is among the top careers for job growth, with an estimated 7% increase in the nursing workforce by 2029. As new students train to enter or advance in the profession, advanced practice RNs (APRNs) must mentor and empower them to integrate evidence-based practice (EBP) into their care.

    August 12, 2021
    Researchers Tie More Cancers, Mortality to NF1 Disorders
    Cancer research

    Researchers Tie More Cancers, Mortality to NF1 Disorders

    The genetic disorder neurofibromatosis type 1 (NF1) is linked to the development of and mortality for more types of cancer than previously identified, researchers reported in results from a new study. They published the findings in JAMA Network Open.

    August 11, 2021
    Coaching Roles Give Nurses New Avenues to Provide Patient-Centered Care
    Oncology nurse influence

    Coaching Roles Give Nurses New Avenues to Provide Patient-Centered Care

    Nurses don’t always have to venture beyond the bedside for unique career change opportunities. Always innovating and evolving, the profession identifies new roles for clinical practice nurses to meet patients’ needs.

    August 10, 2021
    AHRQ Envisions Plan to Address Historical Racism and Inequality in Health Care
    Access to Cancer Care

    AHRQ Envisions Plan to Address Historical Racism and Inequality in Health Care

    Historical and structural racism is a huge barrier to quality health care that has created two tiers of access to care and a lack of understanding of the healthcare system. Government health agencies and leaders, such as the U.S. Agency for Healthcare Research and Quality (AHRQ), are tackling racial disparities in health care directly to change the dynamic to equality for all Americans. AHRQ says it is assessing its own agency and examining how professionals can make the health services research field more diverse and inclusive by building on a foundation that includes producing and promoting the annual National Healthcare Quality and Disparities Report and AHRQ’s social determinants of health database. By recognizing disparities related to race and ethnicity, income, and other social determinants, the organization plans to further address historical racism in health care.

    August 06, 2021
    PCORI Adjusts National Priorities to Align With Addressing Disparities and Improving Healthcare Systems
    Cancer healthcare advocacy

    PCORI Adjusts National Priorities to Align With Addressing Disparities and Improving Healthcare Systems

    Achieving health equity tops the list of the Patient-Centered Outcomes Research Institute’s (PCORI’s) newly updated National Priorities for Research, which the institute released on June 24, 2021.

    August 05, 2021
    Nursing Considerations for Lung Cancer Survivorship Care
    Survivorship care plans

    Nursing Considerations for Lung Cancer Survivorship Care

    As Americans reduce tobacco use and treatment and diagnosis advance, lung cancer survivorship rates are improving; however, it still remains the second most common type of cancer. The growing population needs appropriate survivorship care.

    August 05, 2021
    Nursing Informaticists Are the Backbone of Technology-Driven Care
    Oncology nursing roles

    Nursing Informaticists Are the Backbone of Technology-Driven Care

    Emerging healthcare technologies require a significant investment in time, money, and training. It starts with ensuring that quality improvement efforts are consistent to support positive clinical and patient outcomes, which is why clinical and information technology (IT) representation is critical in making decisions and exploring solutions. Nursing informatics bridges that gap.

    August 03, 2021
    Beyond the Bedside: Oncology Nurses Have Endless Opportunities in Unexpected Careers
    Clinical practice

    Beyond the Bedside: Oncology Nurses Have Endless Opportunities in Unexpected Careers

    As a nurse, you have a diverse arsenal of skills, from clinical competencies and leadership to problem-solving and interprofessional communication. That skillset easily transfers to a variety of careers outside of direct care.

    August 03, 2021
    Oncology Nursing Society Response to Mandated COVID-19 Vaccinations for Nurses and All Healthcare Professionals
    COVID-19

    ONS Response to Mandated COVID-19 Vaccinations for Nurses and All Healthcare Professionals

    On July 26, 2021, the American Nurses Association (ANA) signed onto a statement released by a large group of healthcare systems and other associations in support of healthcare employers mandating nurses and all healthcare personnel be vaccinated against the COVID-19 coronavirus. This is in response to increasing circulation of COVID-19 variants and lagging vaccination rates. Although ONS was not listed on the statement as a supporting organization because of a late request, ONS agrees that vaccinations are critical for healthcare providers, particularly those caring for immunocompromised patients.

    July 30, 2021
    FDA Alerts About Possible Increased Risk of Death Associated With Melphalan Flufenamide
    U.S. Food and Drug Administration (FDA)

    FDA Alerts About Possible Increased Risk of Death Associated With Melphalan Flufenamide

    On July 28, 2021, the U.S. Food and Drug Administration (FDA) reported that a clinical trial (OCEAN, Study OP-103) evaluating melphalan flufenamide (Pepaxto®) with dexamethasone to treat patients with multiple myeloma showed an increased risk of death. 

    July 29, 2021
    HHS Launches Network of Leaders and Organizations to Encourage COVID-19 Vaccinations
    COVID-19

    HHS Launches Network of Leaders and Organizations to Encourage COVID-19 Vaccinations

    As of July 2021, more than 159 million individuals in the United States have been fully vaccinated against the COVID-19 coronavirus, totaling about 48.1% of the U.S. population. However, approximately 173 million others have not, or suggested they will not, receive the vaccination. President Biden’s goal of having 70% of Americans receive at least one vaccine dose and 160 million adults to be fully vaccinated against COVID-19 by July 4, 2021, fell short.

    July 23, 2021
    FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma

    On July 21, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) in combination with lenvatinib (Lenvima®) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting, and are not candidates for curative surgery or radiation. 

    July 23, 2021
    FDA Announces Recall for 12 Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content
    U.S. Food and Drug Administration (FDA)

    FDA Announces Recall for 12 Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content

    On July 19, 2021, the U.S. Food and Drug Administration (FDA) reported Pfizer’s voluntary recall of two lots of varenicline 0.5 mg tablets, two lots of varenicline 1 mg tablets, and eight lots of a varenicline kit of 9.5 mg/1 mg tablets to the patient level because of the presence of N-nitroso-varenicline, a nitrosamine, above the Pfizer-established acceptable daily intake level. Varenicline is a treatment to help patients quit smoking and is intended for short-term use. To date, Pfizer has not received any reports of adverse events that have been related to the recall.

    July 22, 2021
    FDA Announces Recall of One Lot of Topotecan Injection Because of Presence of Particulate Matter
    U.S. Food and Drug Administration (FDA)

    FDA Announces Recall of One Lot of Topotecan Injection Because of Presence of Particulate Matter

    On July 1, 2021, the U.S. Food and Drug Administration (FDA) reported Teva Pharmaceuticals’ June 30, 2021, voluntary recall of lot 31328962B of topotecan injection 4 mg/4 ml. The recall was based on a report that a single vial contained a glass particle, a grey silicone particle, and a translucent, colorless cotton fiber.

    July 22, 2021
    The Case of the Mysterious Myalgia
    Immunotherapy

    The Case of the Mysterious Myalgia

    Randi is a 57-year-old patient who identifies as female. She was diagnosed with clear cell metastatic renal cell carcinoma (mRCC), and her past medical history includes mild hypertension managed with amlodipine and a two-year history of transient musculoskeletal pain managed with tramadol. She reports a family history of cardiovascular disease and rheumatoid arthritis (RA). Her primary care physician suspects Randi is at the beginning stages of fibromyalgia but has not made a conclusive diagnosis because she hasn’t experienced additional symptoms.

    July 20, 2021
    FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease
    U.S. Food and Drug Administration (FDA)

    FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease

    On July 16, 2021, the U.S. Food and Drug Administration (FDA) approved belumosudil (RezurockTM), a kinase inhibitor, for the treatment of chronic graft-versus-host disease (chronic GVHD) in adult and pediatric patients 12 years and older after failure of at least two prior lines of systemic therapy. 

    July 19, 2021
    Diagnose and Treat Hypercalcemia of Malignancy
    Advanced Practice Nursing (APRN)

    Diagnose and Treat Hypercalcemia of Malignancy

    Hypercalcemia of malignancy (HCM) is a common paraneoplastic syndrome associated with poor prognosis that affects approximately 20%–30% of patients with cancer. It’s most often seen in patients with breast, lung, renal, or ovarian cancers; squamous cell carcinoma of the head and neck; multiple myeloma; and certain lymphomas.

    July 15, 2021
    Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship
    Research

    Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship

    More than 40% of patients with melanoma treated with nivolumab or pembrolizumab experience persistent long-term immune-related adverse events (irAEs) for at least 1.5 years, researchers reported in JAMA Oncology.

    July 14, 2021
    Nurse Research AIMS to Increase Screening for Malnutrition and Reduce Bowel Dysfunction
    Oncology nurse researcher

    Nurse Researcher AIMS to Increase Screening for Malnutrition and Reduce Bowel Dysfunction

    Research has identified an association between malnutrition and functional deficits in patients with cancer, regardless of age, and other studies confirm that malnutrition affects treatment tolerability, outcomes, and quality of life for patients with cancer. However, studies have also found that oncology clinicians do not consistently assess for malnutrition and functional deficits in clinical settings. 

    July 13, 2021
    The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity
    Research

    The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity

    Cardiac toxicities are associated with many types of cancer therapies, with both length of and time since treatment increasing a patient’s risk for the adverse event. Anthracycline chemotherapies are among the oldest agents still used for a variety of cancer diagnoses, and as cancer survivorship continues to grow, more patients are presenting with late-onset cardiac complications.

    July 13, 2021
    FDA Approves Daratumumab and Hyaluronidase-Fihj With Pomalidomide and Dexamethasone for Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Daratumumab and Hyaluronidase-Fihj With Pomalidomide and Dexamethasone for Multiple Myeloma

    On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro®) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.

    July 12, 2021
    FDA Grants Regular Approval to Enfortumab Vedotin-Ejfv for Locally Advanced or Metastatic Urothelial Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Regular Approval to Enfortumab Vedotin-Ejfv for Locally Advanced or Metastatic Urothelial Cancer

    On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv ([EV], Padcev®), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer who previously received a programmed death receptor-1 (PD-1) or programmed death-ligand (PD-L1) inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.

    July 09, 2021
    Nursing Considerations for Ovarian Cancer Survivorship Care
    Survivorship

    Nursing Considerations for Ovarian Cancer Survivorship Care

    Historically, ovarian cancer is often diagnosed at advanced stages because of vague symptoms and presentation, but with new advancements in diagnosis and treatment options, patients with the disease are living longer than ever.

    July 09, 2021
    FDA Requires E-Cigarette Brands to Provide Information on Social Media Practices
    U.S. Food and Drug Administration (FDA)

    FDA Requires E-Cigarette Brands to Provide Information on Social Media Practices

    Companies marketing the tobacco brands Aspire, Joyetech, Vaporesso, and Voopoo, which were selected through a systematic process, must share information about social media marketing campaigns that target youth, the U.S. Food and Drug Administration (FDA) announced. The requirements include social media advertising documents and marketing plans, such as planned content to target specific audiences, cost of plans, use of partners and influences, and the number of followers and views broken down by age group.

    July 08, 2021
    Genetic Disorder Reference Sheet: MUTYH-Associated Polyposis
    Genetics & genomics

    Genetic Disorder Reference Sheet: MUTYH-Associated Polyposis

    MUTYH-associated polyposis (MAP) is an autosomal recessive hereditary cancer syndrome. It’s most commonly seen in people of northern European ancestry, where an estimated 1 in 20,000–40,000 have MAP (two pathogenic variants on opposite chromosomes) and 1%–2% have one MUTYH pathogenic variant.

    July 08, 2021
    Standard Minimum Nurse-to-Patient Ratio Improves Outcomes
    Clinical practice

    Standard Minimum Nurse-to-Patient Ratio Improves Outcomes

    Implementing a standard minimum nurse-to-patient ratio lowers mortality, readmission, and length of stay rates, according to findings published in Lancet. 

    July 07, 2021
    Oncology Dietitians Tackle Nutritional Barriers and Dispel Misinformation
    Treatment side effects

    Oncology Dietitians Tackle Nutritional Barriers and Dispel Misinformation

    Because they often face nutrition challenges—such as nausea, taste alterations, difficulty swallowing, and altered gastrointestinal function—that develop during their journey and hinder their nutrition stability, patients with cancer have increased nutrient needs. Oncology dietitians are experts at guiding patients and caregivers through the nutritional process and developing solutions.

    July 06, 2021
    NINR Seeks Nursing Input for 2022–2026 Strategic Plan
    Oncology nursing community

    NINR Seeks Nursing Input for 2022–2026 Strategic Plan

    Nursing science research must look at the whole picture of health, including health equity, social determinants of health, and the translation of science into policy and practice, the National Institute of Health’s (NIH) National Institute for Nursing Research (NINR) said in its approach to developing the 2022–2026 strategic plan.

    July 06, 2021
    Food for Thought: Prevent and Screen for Malnutrition in Patients with Cancer
    Clinical practice

    Food for Thought: Prevent and Screen for Malnutrition in Patients With Cancer

    Malnutrition affects 30%–85% of all patients with cancer, making it one of the most common symptoms for oncology nurses to manage. To help patients achieve the best outcomes, clinicians must understand how and when to screen for malnutrition and how nutritional status affects treatment outcomes and patients’ quality of life.

    July 06, 2021
    USPSTF Recommends Colorectal Cancer Screening Should Begin at 45
    Cancer screening

    USPSTF Recommends Colorectal Cancer Screening Should Begin at 45

    According to the U.S. Preventive Services Task Force (USPSTF), colorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52,980 individuals in the U.S. projected to die from the disease in 2021. After evaluating the current evidence and conducting a modeling study, USPSTF updated its recommendations on colorectal cancer screening.

    July 05, 2021
    FDA Approves Asparaginase Erwinia Chrysanthemi for Leukemia and Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn for Leukemia and Lymphoma

    On June 30, 2021, the U.S. Food and Drug Administration (FDA) approved asparaginase erwinia chrysanthemi (recombinant)-rywn (RylazeTM) as a component of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients one month or older who have developed hypersensitivity to E. coli-derived asparaginase. 

    July 01, 2021
    The Case of the CIA-Combatting Combination
    Clinical practice

    The Case of the CIA-Combatting Combination

    Sofia is a 35-year-old patient who identifies as female who was recently diagnosed with breast cancer and is concerned with experiencing chemotherapy-induced alopecia (CIA) as an adverse event from treatment. She comes in for her first infusion of adriamycin plus cyclophosphamide and is using scalp cooling to prevent hair loss. She works as a project manager, which requires her to keep her camera on for her many daily video calls. She is very anxious about losing her hair and asks you if taking minoxidil in addition to the scalp cooling treatment would guarantee she maintains her hair. 

    June 25, 2021
    • First page « First
    • Previous page
    • …
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Current page 6
    • Page 7
    • Page 8
    • Page 9
    • Page 10
    • …
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲